Updating results

1085 results

Sort: Relevance | Date

Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) (TA452)

NICE is unable to make a recommendation about the use in the NHS of ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53

Technology appraisal guidance Published July 2017

Eliglustat for treating type 1 Gaucher disease (HST5)

HST5 Eliglustat for treating type 1 Gaucher disease 1 Recommendations 1.1 Eliglustat is recommended within

Technology appraisal guidance

Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)

Evidence-based recommendations on ponatinib (Iclusig) for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia in adults

Technology appraisal guidance Published June 2017

Carfilzomib for previously treated multiple myeloma (TA457)

Evidence-based recommendations on carfilzomib (Kyprolis) for treating multiple myeloma in adults

Technology appraisal guidance Published July 2017

Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)

Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for treating advanced HER2-positive breast cancer that has been treated before

Technology appraisal guidance Published July 2017 Last updated November 2017

Tivozanib for treating advanced renal cell carcinoma (TA512)

Evidence-based recommendations on tivozanib (Fotivda) for previously untreated advanced renal cell carcinoma (RCC/kidney cancer) in adults

Technology appraisal guidance Published March 2018

Brodalumab for treating moderate to severe plaque psoriasis (TA511)

Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published March 2018

Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA510)

Evidence-based recommendations on daratumumab (Darzalex) for relapsed or refractory multiple myeloma in adults

Technology appraisal guidance Published March 2018

Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)

Evidence-based recommendations on cetuximab (Erbitux) for treating recurrent or metastatic squamous cell cancer of the head and neck in adults

Technology appraisal guidance Published August 2017

Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (TA472)

Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for adults with follicular lymphoma unresponsive to treatment with rituximab

Technology appraisal guidance Published August 2017

Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471)

Evidence-based recommendations on eluxadoline (Truberzi) for treating irritable bowel syndrome (IBS) with diarrhoea in adults

Technology appraisal guidance Published August 2017

Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) (TA469)

NICE is unable to make a recommendation about the use in the NHS of idelalisib with ofatumumab for treating chronic lymphocytic leukaemia because no evidence

Technology appraisal guidance Published August 2017

Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) (TA468)

NICE was unable to make a recommendation about the use in the NHS of methylnaltrexone bromide for treating opioid-induced constipation because no evidence was

Technology appraisal guidance Published August 2017

Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)

Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults

Technology appraisal guidance Published July 2017

Asfotase alfa for treating paediatric-onset hypophosphatasia (HST6)

HST6 Asfotase alfa for treating paediatric-onset hypophosphatasia 1 Recommendations 1.1 Asfotase alfa is

Technology appraisal guidance

Cabozantinib for previously treated advanced renal cell carcinoma (TA463)

Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma (kidney cancer) in adults

Technology appraisal guidance Published August 2017

Bisphosphonates for treating osteoporosis (TA464)

Evidence-based recommendations on bisphosphonates (alendronic acid; ibandronic acid; risedronate sodium; zoledronic acid) for treating osteoporosis in adults

Technology appraisal guidance Published August 2017 Last updated July 2019

Baricitinib for moderate to severe rheumatoid arthritis (TA466)

Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults

Technology appraisal guidance Published August 2017

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)

Evidence-based recommendations on nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults

Technology appraisal guidance Published July 2017

Roflumilast for treating chronic obstructive pulmonary disease (TA461)

Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease (COPD) in adults with chronic bronchitis

Technology appraisal guidance Published July 2017

Collagenase clostridium histolyticum for treating Dupuytren's contracture (TA459)

Evidence-based recommendations on collagenase clostridium histolyticum (Xiapex) for treating Dupuytren’s contracture in adults

Technology appraisal guidance Published July 2017

Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)

Evidence-based recommendations on dapagliflozin (Forxiga) in combination therapy for treating type 2 diabetes in adults

Technology appraisal guidance Published June 2013 Last updated November 2016

Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) (TA286)

NICE is unable to recommend the use in the NHS of loxapine inhalation for treating acute agitation and disturbed behaviours associated with

Technology appraisal guidance Published May 2013

Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)

Evidence-based recommendations on aripiprazole (Abilify) for treating moderate to severe manic episodes in adolescents with bipolar I disorder

Technology appraisal guidance Published July 2013

Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)

Evidence-based recommendations on aflibercept (Eylea) solution for injection for treating wet age-related macular degeneration

Technology appraisal guidance Published July 2013

Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (TA308)

Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis

Technology appraisal guidance Published March 2014

Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)

Evidence-based recommendations on enzalutamide (Xtandi) for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen

Technology appraisal guidance Published July 2014

Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)

Evidence-based recommendations on ipilimumab (Yervoy) for previously treated advanced (unresectable or metastatic) melanoma

Technology appraisal guidance Published December 2012

Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis (TA276)

Evidence-based recommendations on colistimethate sodium and tobramycin dry powders for inhalation for pseudomonas lung infection in cystic fibrosis

Technology appraisal guidance Published March 2013

Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures (TA279)

Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for osteoporotic vertebral compression fractures

Technology appraisal guidance Published April 2013

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)

Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing recurrent DVT and pulmonary embolism

Technology appraisal guidance Published July 2012

Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)

Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours

Technology appraisal guidance Published October 2012

Ivabradine for treating chronic heart failure (TA267)

Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure

Technology appraisal guidance Published November 2012

Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323)

Evidence-recommendations on erythropoiesis-stimulation agents (epoetin alfa, beta, theta and zeta and darbepoetin alfa) for anaemia in people with cancer..

Technology appraisal guidance Published November 2014

Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA326)

Evidence-based recommendations on imatinib (Glivec) for adjuvant treatment of gastrointestinal stromal tumours (cancers in the digestive track)

Technology appraisal guidance Published November 2014

Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)

Evidence-based recommendations on ranibizumab (Lucentis) for treating sight problems caused by macular oedema secondary to retinal vein occlusion

Technology appraisal guidance Published May 2013

Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) (TA277)

NICE is unable to recommend the use in the NHS of methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness...

Technology appraisal guidance Published March 2013

Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285)

Evidence-based recommendations on bevacizumab (Avastin) in combination with gemcitabine and carboplatin for treating the first recurrence of

Technology appraisal guidance Published May 2013

Alemtuzumab for treating relapsing‑remitting multiple sclerosis (TA312)

Evidence-based recommendations on alemtuzumab (Lemtrada) for treating active relapsing–remitting multiple sclerosis (MS)

Technology appraisal guidance Published May 2014

Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (TA305)

Evidence-based recommendations on aflibercept (Eylea) for visual impairment caused by macular oedema secondary to central retinal vein occlusion

Technology appraisal guidance Published February 2014

Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)

Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis (MS/RRMS)

Technology appraisal guidance Published August 2014

Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249)

Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in atrial fibrillation (AF)

Technology appraisal guidance Published March 2012

Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (TA258)

Evidence-based recommendations on erlotinib (Tarceva) for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer

Technology appraisal guidance Published June 2012

Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)

Evidence-based recommendations on cetuximab (Erbitux) and panitumumab (Vectibix) for previously untreated RAS wild-type metastatic colorectal cancer in adults

Technology appraisal guidance Published March 2017 Last updated September 2017

Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) (TA435)

NICE was unable to make a recommendation about the use in the NHS of tenofovir alafenamide for treating chronic hepatitis B because no evidence submission was

Technology appraisal guidance Published March 2017

Elotuzumab for previously treated multiple myeloma (terminated appraisal) (TA434)

NICE was unable to make a recommendation about the use in the NHS of elotuzumab for previously treated multiple myeloma because no evidence submission was

Technology appraisal guidance Published March 2017

Apremilast for treating active psoriatic arthritis (TA433)

Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis in adults

Technology appraisal guidance Published February 2017

Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) (TA438)

NICE is unable to make a recommendation about the use in the NHS of alectinib for anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

Technology appraisal guidance Published March 2017

Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)

Evidence-based recommendations on sofosbuvir–velpatasvir (Epclusa) for treating chronic hepatitis C in adults

Technology appraisal guidance Published January 2017

Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST3)

HST3 Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene 1 Guidance

Technology appraisal guidance